See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: March 28 2006

Cancer/Tumors or Stem Cell Transplant Dyslipidemia Organ Transplant

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Cancer/Tumors or Stem Cell Transplant

This study is evaluating the safety and efficacy of a drug for the prevention of oral mucositis (mouth inflammation), a condition that is common in cancer patients receiving myeloablative chemotherapy. Candidates who are at least 18 years old, have certain cancers that warrant myeloablative chemotherapy and require autologous stem cell support, have adequate organ function, are not pregnant or breast-feeding, and have not been diagnosed with AIDS or Hepatitis B/C, may qualify. The research site is in New York City.

More Information

Please see or



This study will evaluate the effects of once-daily fenofibric acid monotherapy and simvastatin monotherapy with fenofibric acid and simvastatin combination therapy on CHD lipid risk factors in people with mixed dyslipidemia. Volunteers who are 18 years old and who meet certain test result requirements may be eligible. The research site is in San Antonio, Texas.

More Information

Please see


Organ Transplant

The goal of this study is evaluate whether rituximab, in combination with the commonly used cancer drugs cyclophosphamide and prednisone, is effective in treating post-transplant lymphoproliferative disease (PTLD) after a solid organ transplant. Patients who are less than 31 years old who have PTLD following a solid organ transplant may be eligible. The research site is in Cincinnati, Ohio.

More Information

Please see


Copyright 2006 CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.